Redeye is positive about the large SEK23m order from ClearPoint Neuro, as we believe it provides much-needed confidence in CLS’s accelerated commercial strategy within the Prism business. Furthermore, we view today’s announcement as supportive of our projected sales ramp-up and reiterate our base case valuation of the company.
LÄS MER
